Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Deferred Taxes (2016 - 2025)

Anika Therapeutics (ANIK) has disclosed Deferred Taxes for 15 consecutive years, with -$25000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Deferred Taxes fell 110.68% to -$25000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was -$7000.0, a 102.69% decrease, with the full-year FY2025 number at -$7000.0, down 102.69% from a year prior.
  • Deferred Taxes was -$25000.0 for Q4 2025 at Anika Therapeutics, down from $3000.0 in the prior quarter.
  • In the past five years, Deferred Taxes ranged from a high of $2.4 million in Q2 2021 to a low of -$2.8 million in Q4 2021.
  • A 5-year average of -$655500.0 and a median of -$228500.0 in 2022 define the central range for Deferred Taxes.
  • Biggest YoY gain for Deferred Taxes was 261.84% in 2021; the steepest drop was 1055.19% in 2021.
  • Anika Therapeutics' Deferred Taxes stood at -$2.8 million in 2021, then surged by 36.1% to -$1.8 million in 2022, then fell by 3.6% to -$1.8 million in 2023, then surged by 112.7% to $234000.0 in 2024, then crashed by 110.68% to -$25000.0 in 2025.
  • Per Business Quant, the three most recent readings for ANIK's Deferred Taxes are -$25000.0 (Q4 2025), $3000.0 (Q3 2025), and -$3000.0 (Q2 2025).